Quick Answer: what each product is approved for
- • Type 2 diabetes
- • Once weekly
- • 0.25 → 0.5 → 1 → 2 mg
- • Not approved for weight loss
- • Chronic weight management
- • CV risk reduction
- • Once weekly
- • 0.25 → 2.4 mg over 16 weeks
- • Type 2 diabetes
- • Once daily, oral
- • 3 → 7 → 14 mg
- • Not approved for weight loss
Semaglutide is also approved as Wegovy tablets (weight management and CV risk reduction) and as Ozempic tablets (type 2 diabetes). Both are covered below.
The Bottom Line
- • Start low, step up on a schedule
- • At least 4 weeks (or 30 days) per step
- • Escalation exists to blunt GI adverse reactions
- • The same boxed thyroid C-cell tumor warning
- • The indication each is approved for
- • The ceiling dose (2 mg vs 2.4 mg vs 7.2 mg)
- • Weekly injection vs daily tablet
- • Tablets require an empty stomach and a 30-minute wait
- • Only the Wegovy label directs delaying a step if a dose is not tolerated
What We'll Cover
- 1. The semaglutide dosage chart, all products
- 2. Ozempic dosing (type 2 diabetes)
- 3. Wegovy dose schedule (weight management)
- 4. Rybelsus dosing and the oral tablets
- 5. Why every label titrates instead of starting high
- 6. What the labels say about missed doses
- 7. Off-label use: Ozempic and Rybelsus for weight loss
- 8. Compounded semaglutide has no approved dose
- 9. What the prescriber decides, not the chart
Most semaglutide dosing content on the internet quietly merges three different drugs into one chart. That is the mistake worth avoiding, because the products are not interchangeable and their labels are not the same document. Ozempic, Wegovy, and Rybelsus contain the same active ingredient, and that is where the similarity stops. They have different approved uses, different escalation schedules, different ceilings, and in two cases a different route of administration entirely. Below is what each FDA-approved label actually specifies, reported as-is.
How to read this page. Everything below is a report of what the FDA prescribing information specifies. It is not a protocol, not a recommendation, and not a starting point for self-treatment. Semaglutide is a prescription medication. Selecting a product, a starting dose, an escalation pace, and a maintenance dose is a clinical decision made by a licensed prescriber who knows your history.
The Semaglutide Dosage Chart, All Products
This is the whole semaglutide family in one view. Each row reflects that product's own FDA label. Note that two products in this table are approved only for type 2 diabetes, and two are approved for chronic weight management.
| Product | Form & frequency | FDA-approved use | Labeled dose steps |
|---|---|---|---|
| Ozempic injection | Subcutaneous, once weekly | Type 2 diabetes; CV risk reduction and kidney outcomes in T2D | 0.25 → 0.5 → 1 → 2 mg |
| Wegovy injection | Subcutaneous, once weekly | Chronic weight management; CV risk reduction; noncirrhotic MASH with F2-F3 fibrosis | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg (max 7.2 mg for weight reduction in adults) |
| Wegovy tablets | Oral, once daily | Chronic weight management; CV risk reduction | 1.5 → 4 → 9 → 25 mg |
| Rybelsus tablets | Oral, once daily | Type 2 diabetes; CV risk reduction in high-risk T2D | 3 → 7 → 14 mg |
| Ozempic tablets | Oral, once daily | Type 2 diabetes; CV risk reduction in high-risk T2D | 1.5 → 4 → 9 mg |
The detail almost everyone gets wrong: Rybelsus and Ozempic tablets are both oral semaglutide, and their shared FDA label states in the first line of the dosing section that the two are not substitutable on a milligram-to-milligram basis. A 7 mg Rybelsus tablet and a 4 mg Ozempic tablet are not the same thing written two ways. That is exactly the kind of assumption that makes dose-conversion guesswork dangerous.
Ozempic Dosing (Type 2 Diabetes)
Ozempic is semaglutide injection approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It is not approved for weight management.
| Stage | Dose | What the label specifies |
|---|---|---|
| Weeks 1-4 (initiation) | 0.25 mg once weekly | Initiation dosage for 4 weeks |
| Week 5 onward | 0.5 mg once weekly | Increase after 4 weeks on 0.25 mg |
| Optional step | 1 mg once weekly | If additional glycemic control is needed after at least 4 weeks on 0.5 mg |
| Optional step | 2 mg once weekly | If additional glycemic control is needed after at least 4 weeks on 1 mg. Maximum recommended dosage. |
| T2D with chronic kidney disease | 1 mg once weekly | Label directs increasing to the 1 mg maintenance dosage after at least 4 weeks on 0.5 mg |
Administration details from the label: inject once weekly on the same day each week, at any time of day, with or without meals, subcutaneously in the abdomen, thigh, or upper arm. The day of the week can be changed as long as at least 48 hours separate two doses. The label states no dose adjustment is recommended for renal impairment or for hepatic impairment.
If you are pricing a semaglutide program rather than reading its label, our verified semaglutide cost guide collects real published monthly prices from clinics, and Ozempic alternatives covers what else is on the market.
Wegovy Dose Schedule (Chronic Weight Management)
Wegovy injection is the semaglutide product approved for weight-related use. Its label covers reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition; and treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults under accelerated approval. All uses are in combination with a reduced calorie diet and increased physical activity.
Wegovy has the longest labeled titration of any semaglutide product. The escalation is identical across all approved indications; only the maintenance dose differs.
| Weeks | Once-weekly subcutaneous dose | Phase |
|---|---|---|
| 1 through 4 | 0.25 mg | Starting dosage |
| 5 through 8 | 0.5 mg | Escalation |
| 9 through 12 | 1 mg | Escalation |
| 13 through 16 | 1.7 mg | Escalation |
| 17 and onward | Maintenance (see below) | Maintenance |
The label sets maintenance by indication. For weight reduction in adults, maintenance is 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended; for patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated, the dosage may be increased to a maximum of 7.2 mg once weekly. For cardiovascular risk reduction in adults, maintenance is 2.4 mg (recommended) or 1.7 mg. For weight reduction in patients aged 12 and older, maintenance is 2.4 mg (recommended) or 1.7 mg. For noncirrhotic MASH, maintenance is 2.4 mg, and the label allows decreasing to 1.7 mg if 2.4 mg is not tolerated, with reescalation considered later.
The escalation is allowed to slow down
The Wegovy label states directly that if a patient does not tolerate a dose during escalation, the prescriber should consider delaying escalation for 4 weeks. The schedule is a maximum pace, not a mandatory one. Nothing in the label instructs a patient to push through a dose they cannot tolerate.
Wegovy tablets: the oral weight-management schedule
Semaglutide is also approved as Wegovy tablets for cardiovascular risk reduction and weight reduction in adults. The tablet titration runs on 30-day steps rather than 4-week blocks.
| Days | Once-daily oral dose | Phase |
|---|---|---|
| 1 through 30 | 1.5 mg | Starting dosage |
| 31 through 60 | 4 mg | Escalation |
| 61 through 90 | 9 mg | Escalation |
| 91 and onward | 25 mg | Maintenance |
The tablet has strict administration rules that the injection does not. Take it orally once daily on an empty stomach in the morning with water, up to 4 ounces and no other liquid. Swallow whole; do not split, crush, chew, or dissolve. Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Those rules are not fussiness. Oral semaglutide absorption depends on them.
The Wegovy label also contains explicit instructions for switching between the injection and the tablet, in both directions, at specified doses. That is a same-brand, same-molecule switch written into a single label. It is not a template for converting between different drugs, and it is a prescriber's decision. If you are weighing an oral option, our GLP-1 pill guide covers what oral GLP-1 medications exist and how they differ from injections.
Rybelsus Dosing and the Oral Diabetes Tablets
Rybelsus is oral semaglutide approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. It is not approved for weight management.
| Days | Rybelsus (once daily) | Ozempic tablets (once daily) |
|---|---|---|
| 1 through 30 (initiation) | 3 mg | 1.5 mg |
| 31 through 60 | 7 mg | 4 mg |
| 61 onward (maintenance) | 7 mg, or 14 mg if additional glycemic control is needed | 4 mg, or 9 mg if additional glycemic control is needed |
One line in this label deserves emphasis because it is unusual and it is easy to misunderstand. For both products, the label states that the 30-day initiation dose is not effective for glycemic control. It exists to let the gastrointestinal tract adapt. A patient a week into Rybelsus 3 mg whose glucose has not moved is seeing exactly what the label predicts.
Administration matches the Wegovy tablet rules: empty stomach, morning, water only, up to 4 ounces, swallow whole, wait at least 30 minutes before food, other beverages, or other oral medications. The label also states the two oral products are not substitutable on a milligram-to-milligram basis and gives specific instructions for switching between them after the initiation phase.
Why Every Label Titrates Instead of Starting High
Every semaglutide label gives the same reason for the escalation schedule: to reduce the risk of gastrointestinal adverse reactions. That is stated explicitly in the dosing section of each product, cross-referenced to the warnings on severe gastrointestinal adverse reactions.
The most common adverse reactions reported in the labels reflect that. For Ozempic, the label lists nausea, vomiting, diarrhea, abdominal pain, and constipation as occurring in at least 5% of treated patients. For Rybelsus and Ozempic tablets, the label lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation at that same threshold. Wegovy's list at 5% or greater incidence is longer and includes nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, and hair loss.
Every semaglutide product carries a boxed warning
All semaglutide products carry a boxed warning for risk of thyroid C-cell tumors. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; whether it causes such tumors including medullary thyroid carcinoma in humans has not been determined. The labels contraindicate use in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in patients with a serious hypersensitivity reaction to semaglutide. Read the full label with your prescriber.
What the Labels Say About Missed Doses
The missed-dose instructions are product-specific, and this is another place where merging the products into one rule goes wrong.
- Ozempic injection. If a dose is missed, the label says to administer it as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip it and resume the regular weekly schedule.
- Wegovy injection. If one dose is missed and the next scheduled dose is more than 2 days away, administer as soon as possible; if it is less than 2 days away, skip it and resume on schedule. If 2 or more consecutive doses are missed, the label directs reinitiating dosage escalation at a lower dosage.
- Wegovy tablets, Rybelsus, Ozempic tablets. If a dose is missed, skip it and take the next dose the following day. The labels also state not to take more than one tablet per day.
Report a missed dose to your prescriber rather than improvising, especially the Wegovy case where the label contemplates restarting escalation.
Off-Label Use: Ozempic and Rybelsus for Weight Loss
This distinction is regularly blurred in marketing, so here it is plainly. Ozempic and Rybelsus are approved for type 2 diabetes. Wegovy is approved for chronic weight management. When a clinician prescribes Ozempic or Rybelsus for weight loss, that is off-label prescribing. Off-label prescribing is legal and common in US medicine, and it is a decision made by a licensed prescriber. It is not the same as FDA approval for that use, and a page that presents Ozempic as an approved weight-loss drug is telling you something false.
The same distinction runs through the tirzepatide products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Our tirzepatide dosing guide runs the same label-by-label breakdown for those, and semaglutide vs tirzepatide compares the two molecules directly. For the full field, see the GLP-1 medications list.
Coverage follows the indication more often than people expect. A plan that covers Ozempic for a diabetes diagnosis may decline it when the stated purpose is weight loss, which is one reason the cash-pay market for these drugs exists at all. Our cheapest GLP-1 without insurance guide covers the price side of that gap.
Compounded Semaglutide Has No FDA-Approved Dose
Compounded semaglutide is not an FDA-approved drug. FDA does not review compounded products for safety, effectiveness, or quality before they are marketed, and there is no FDA-approved dosing schedule for a compounded product. Every dosing chart on this page describes an approved product. None of it transfers to a compounded vial.
FDA has been specific about what goes wrong. The agency has stated it received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide products, resulting from patients measuring and self-administering incorrect doses and from health care professionals miscalculating doses. FDA has also reported adverse events that may relate to patients being prescribed compounded semaglutide or tirzepatide at doses beyond the approved label, taking doses more frequently, or escalating faster than the approved titration schedule. Reported symptoms included nausea, vomiting, diarrhea, abdominal pain, and constipation, with some patients seeking medical attention.
Where the arithmetic breaks
Approved semaglutide pens deliver a fixed dose per injection. Compounded semaglutide is often supplied as a multi-dose vial with a syringe, and instructions may be written in units or milliliters rather than milligrams. Converting between those requires knowing the concentration of that specific vial. FDA has also warned about semaglutide salt forms, such as semaglutide sodium and semaglutide acetate, which are different active ingredients than the one in the approved drugs and which FDA has said it is not aware of any lawful basis to use in compounding.
If you are considering a compounded product for cost reasons, read our compounded semaglutide guide first, and compare against the brand pricing in the tirzepatide cost guide and semaglutide cost guide.
What the Prescriber Decides, Not the Chart
A label schedule is a framework. The clinical decisions inside it belong to a licensed prescriber who can see your history, your other medications, and how you actually respond. Those decisions include:
- Which product, if any. The indication drives this, and so does whether you can tolerate a daily empty-stomach tablet routine versus a weekly injection.
- Whether to escalate on schedule. Both the Wegovy and Ozempic labels frame escalation as conditional, and Wegovy explicitly contemplates delaying a step by 4 weeks.
- Which maintenance dose to hold at. Wegovy's label names both 1.7 mg and 2.4 mg as maintenance options for weight reduction in adults, with tolerability as a stated consideration.
- Whether to stop or step down. The MASH section of the Wegovy label describes decreasing to 1.7 mg and considering reescalation later. Stepping down is a labeled clinical option, not a failure.
- Interactions and monitoring. The labels flag monitoring blood glucose in patients with diabetes and warn about hypoglycemia with concomitant insulin or insulin secretagogues. The Wegovy label also states that using it with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended.
That last point is worth repeating because stacking is a real pattern in the cash-pay market. The Wegovy label states directly that concomitant use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
Related reading
- Side effects by product: Ozempic side effects and tirzepatide side effects
- Product comparison: Wegovy vs Ozempic, the same molecule at different approved doses and indications
- Programs: best GLP-1 weight-loss programs compares the clinical wrap around the prescription
- Find a clinic: browse GLP-1 and weight-loss clinics by state
Compare GLP-1 Programs and Prices
Verified cash-pay pricing, program inclusions, and clinic options in one place.
Browse Weight-Loss ClinicsFrequently Asked Questions
What is the semaglutide dosing schedule?▼
There is no single semaglutide dosing schedule. Semaglutide is sold as several distinct FDA-approved products, and each has its own labeled titration. Ozempic injection (type 2 diabetes) starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly, with optional increases to 1 mg and then 2 mg after at least 4 weeks at each step. Wegovy injection (chronic weight management and cardiovascular risk reduction) climbs 0.25 mg, 0.5 mg, 1 mg, 1.7 mg over 16 weeks to a 2.4 mg maintenance dose. Rybelsus is an oral tablet for type 2 diabetes dosed 3 mg daily for 30 days, then 7 mg, then optionally 14 mg. Your prescriber decides which product and which dose is appropriate for you.
What is the Ozempic dosing schedule?▼
The Ozempic label specifies initiation at 0.25 mg injected subcutaneously once weekly for 4 weeks. After 4 weeks the dosage increases to 0.5 mg once weekly. If additional glycemic control is needed, the label allows an increase to 1 mg once weekly after at least 4 weeks on 0.5 mg, and then to 2 mg once weekly after at least 4 weeks on 1 mg. The maximum recommended dosage is 2 mg once weekly. For adults with type 2 diabetes and chronic kidney disease, the label directs increasing to the 1 mg maintenance dosage after at least 4 weeks on 0.5 mg. Ozempic is approved for type 2 diabetes, not for weight loss. Only a licensed prescriber can set or change a dose.
What is the Wegovy dose schedule?▼
The Wegovy injection label specifies a 16-week escalation before maintenance: 0.25 mg once weekly for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, then maintenance from week 17 onward. The recommended maintenance dosage for weight reduction in adults is 2.4 mg once weekly, with 1.7 mg as the alternative. The label states that patients who tolerate 2.4 mg for at least 4 weeks and need additional weight reduction may be increased to a maximum of 7.2 mg once weekly. If a dose is not tolerated during escalation, the label says to consider delaying the next step by 4 weeks. The prescriber makes that call.
What is the Rybelsus dosage schedule?▼
Rybelsus is oral semaglutide approved for type 2 diabetes. The label specifies 3 mg orally once daily for days 1 through 30, and states plainly that this starting dosage is not effective for glycemic control, then 7 mg once daily for days 31 through 60. From day 61 onward the dosage stays at 7 mg, or increases to 14 mg once daily if additional glycemic control is needed. The tablet must be taken on an empty stomach in the morning with no more than 4 ounces of water, swallowed whole, with at least 30 minutes before food, other drinks, or other oral medications. Rybelsus is not approved for weight loss.
How long does it take to reach the full semaglutide dose?▼
It depends on the product. Wegovy injection has the longest labeled ramp: 16 weeks of escalation before the 2.4 mg maintenance dose begins at week 17. Ozempic reaches its 0.5 mg maintenance dose after 4 weeks, and reaching 2 mg takes at least 12 weeks of stepped increases. Rybelsus reaches 7 mg at day 31 and 14 mg no earlier than day 61. Wegovy tablets reach the 25 mg maintenance dose at day 91. Every label states the escalation exists to reduce the risk of gastrointestinal adverse reactions. The Wegovy label goes further and directs prescribers to consider delaying escalation by 4 weeks if a dose is not tolerated. Actual timing is a clinical decision, not a fixed calendar.
Is compounded semaglutide dosed the same as Ozempic or Wegovy?▼
No, and this is a real safety issue. Compounded semaglutide is not an FDA-approved product, so it carries no FDA-approved dosing schedule and has not been reviewed by FDA for safety, effectiveness, or quality. FDA has stated it received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, including patients measuring incorrect doses and clinicians miscalculating doses. FDA has also flagged reports of patients being prescribed compounded semaglutide at doses beyond the approved label, or titrated faster than the label allows. Compounded products are frequently dosed in units or milliliters rather than milligrams, which is where the arithmetic goes wrong.
Can Ozempic be prescribed for weight loss?▼
Ozempic is FDA-approved for type 2 diabetes, for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and for kidney outcomes in adults with type 2 diabetes and chronic kidney disease. It is not approved for weight management. A clinician can legally prescribe an approved drug off-label, and prescribing Ozempic for weight loss is off-label prescribing. Wegovy is the semaglutide product FDA approved for chronic weight management. Off-label use is a decision between a patient and a licensed prescriber, and insurers often treat it differently for coverage.
Medical Disclaimer
This guide is for educational purposes only and is not medical advice. It reports dosing schedules published in FDA-approved prescribing information so that patients can read the same source their clinician does. It is not a treatment protocol, and it does not recommend starting, stopping, changing, combining, or converting any dose of any medication. Semaglutide is a prescription medication with a boxed warning and contraindications. Only a licensed clinician who knows your medical history can determine whether any semaglutide product is appropriate for you and at what dose. Labels are updated; confirm current prescribing information with your clinician or pharmacist. VitalityScout is not affiliated with Novo Nordisk. If you experience severe or persistent symptoms, contact a healthcare provider.
Sources & References
- • OZEMPIC (semaglutide) injection prescribing information (DailyMed, Novo Nordisk) — indications, dosage and administration, missed dose, adverse reactions, boxed warning
- • WEGOVY (semaglutide) injection and tablets prescribing information (DailyMed, Novo Nordisk) — escalation Table 1 and Table 2, maintenance by indication, switching, missed dose
- • RYBELSUS and OZEMPIC (oral semaglutide) tablets prescribing information (DailyMed, Novo Nordisk) — oral titration, non-substitutability, administration instructions
- • FDA: concerns with unapproved GLP-1 drugs used for weight loss — dosing errors with compounded semaglutide, salt forms, fraudulent products
- • Ozempic full prescribing information (PDF), Wegovy (PDF), Rybelsus (PDF) — manufacturer-hosted full prescribing information